Menu Search
Equities

Nuwellis Inc

22SA:FRA

Nuwellis Inc

Actions
  • Price (EUR)0.2605
  • Today's Change-0.002 / -0.76%
  • Shares traded2.50k
  • 1 Year change-89.90%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

  • Revenue in USD (TTM)8.90m
  • Net income in USD-19.93m
  • Incorporated2002
  • Employees59.00
  • Location
    Nuwellis Inc12988 Valley View RdEDEN PRAIRIE 55344-3657United StatesUSA
  • Phone+1 (952) 345-4200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.nuwellis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.